Literature DB >> 21084491

HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies.

M Peressin1, V Holl, S Schmidt, T Decoville, D Mirisky, A Lederle, M Delaporte, K Xu, A M Aubertin, C Moog.   

Abstract

Langerhans cells (LCs) and interstitial dendritic cells (IDCs) may be among the first human immunodeficiency virus type 1 (HIV-1) targets after sexual transmission. We generated cells of these types by differentiation of purified CD34(+) cord blood cells. After in vitro infection with R5-tropic strains, we obtained similar percentages of infected cells for both dendritic cell (DC) subsets. Moreover, LC infection was not increased by blockage of langerin by antilangerin. These results indicate that, under our experimental conditions, there was no evidence of any preference of HIV replication in LCs versus IDCs. The inhibitory activity of HIV-1-specific IgAs and IgGs against HIV-1 replication in LCs and IDCs was analyzed. We found that neutralizing antibodies inhibit HIV-1 infection of both DC subsets. Interestingly, HIV-1 was inhibited more efficiently by the IgGs than the corresponding IgA, due to an Fcγ receptor-dependent mechanism. Moreover, nonneutralizing inhibitory IgGs were able to inhibit infection of both LCs and IDCs. These results underline the importance of HIV-1 inhibition by the binding of the Fc part of IgGs to Fcγ receptors and suggest that the induction of neutralizing and nonneutralizing inhibitory IgGs in addition to neutralizing IgAs at mucosal sites may contribute to protection against sexual transmission of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084491      PMCID: PMC3020030          DOI: 10.1128/JVI.01619-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

Review 1.  Langerin functions as an antiviral receptor on Langerhans cells.

Authors:  Michiel van der Vlist; Teunis B H Geijtenbeek
Journal:  Immunol Cell Biol       Date:  2010-03-23       Impact factor: 5.126

Review 2.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

3.  DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGF-beta, and anti-inflammatory agents.

Authors:  Miguel Relloso; Amaya Puig-Kröger; Oscar Muñiz Pello; José Luis Rodríguez-Fernández; Gonzalo de la Rosa; Natividad Longo; Joaquín Navarro; Mari Angeles Muñoz-Fernández; Paloma Sánchez-Mateos; Angel L Corbí
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

4.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

Authors:  J Y Xu; M K Gorny; T Palker; S Karwowska; S Zolla-Pazner
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages.

Authors:  Vincent Holl; Stéphane Hemmerter; Renaud Burrer; Sylvie Schmidt; Alain Bohbot; Anne-Marie Aubertin; Christiane Moog
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

6.  Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Authors:  John R Mascola; Mark K Louder; Christine Winter; Ranjani Prabhakara; Stephen C De Rosa; Daniel C Douek; Brenna J Hill; Dana Gabuzda; Mario Roederer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 7.  Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy.

Authors:  Katherine Kedzierska; Rula Azzam; Philip Ellery; Johnson Mak; Anthony Jaworowski; Suzanne M Crowe
Journal:  J Clin Virol       Date:  2003-02       Impact factor: 3.168

8.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

9.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha.

Authors:  C Caux; B Vanbervliet; C Massacrier; C Dezutter-Dambuyant; B de Saint-Vis; C Jacquet; K Yoneda; S Imamura; D Schmitt; J Banchereau
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  12 in total

1.  Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Authors:  Derseree Archary; Rong Rong; Michelle L Gordon; Saikat Boliar; Maphuti Madiga; Elin S Gray; Anne-Sophie Dugast; Tandile Hermanus; Philip J R Goulder; Hoosen M Coovadia; Lise Werner; Lynn Morris; Galit Alter; Cynthia A Derdeyn; Thumbi Ndung'u
Journal:  Virology       Date:  2012-09-18       Impact factor: 3.616

2.  A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.

Authors:  Brian Moldt; Niccole Schultz; D Cameron Dunlop; Michael D Alpert; Jackson D Harvey; David T Evans; Pascal Poignard; Ann J Hessell; Dennis R Burton
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

3.  Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Authors:  C Moog; N Dereuddre-Bosquet; J-L Teillaud; M E Biedma; V Holl; G Van Ham; L Heyndrickx; A Van Dorsselaer; D Katinger; B Vcelar; S Zolla-Pazner; I Mangeot; C Kelly; R J Shattock; R Le Grand
Journal:  Mucosal Immunol       Date:  2013-04-17       Impact factor: 7.313

4.  Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.

Authors:  Katja Klein; Ronald S Veazey; Ranjit Warrier; Peter Hraber; Lara A Doyle-Meyers; Viviana Buffa; Hua-Xin Liao; Barton F Haynes; George M Shaw; Robin J Shattock
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

5.  Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production.

Authors:  Alexandre Lederle; Bin Su; Vincent Holl; Julien Penichon; Sylvie Schmidt; Thomas Decoville; Géraldine Laumond; Christiane Moog
Journal:  Sci Rep       Date:  2014-08-18       Impact factor: 4.379

6.  Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.

Authors:  Mark D Hicar; Xuemin Chen; Chidananda Sulli; Trevor Barnes; Jason Goodman; Hakimuddin Sojar; Bryan Briney; Jordan Willis; Valentine U Chukwuma; Spyros A Kalams; Benjamin J Doranz; Paul Spearman; James E Crowe
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

7.  Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.

Authors:  Rena D Astronomo; Sampa Santra; Lamar Ballweber-Fleming; Katharine G Westerberg; Linh Mach; Tiffany Hensley-McBain; Laura Sutherland; Benjamin Mildenberg; Georgeanna Morton; Nicole L Yates; Gregory J Mize; Justin Pollara; Florian Hladik; Christina Ochsenbauer; Thomas N Denny; Ranjit Warrier; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayapan; Jaranit Kaewkungwal; Guido Ferrari; George M Shaw; Shi-Mao Xia; Hua-Xin Liao; David C Montefiori; Georgia D Tomaras; Barton F Haynes; Juliana M McElrath
Journal:  EBioMedicine       Date:  2016-11-21       Impact factor: 8.143

Review 8.  Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.

Authors:  Bruce D Wines; Hugh Billings; Milla R Mclean; Stephen J Kent; P Mark Hogarth
Journal:  Curr HIV Res       Date:  2017       Impact factor: 1.581

Review 9.  HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells.

Authors:  Charles R Rinaldo
Journal:  Scientifica (Cairo)       Date:  2013-05-07

Review 10.  Which Antibody Functions are Important for an HIV Vaccine?

Authors:  Bin Su; Christiane Moog
Journal:  Front Immunol       Date:  2014-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.